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Introduction
Hepatitis C virus (HCV) infection is an important cause 
of chronic liver disease that may lead to cirrhosis and 
hepatocellular carcinoma.1,2 The primary goal of anti-HCV 
therapy is the permanent eradication of the virus, or a sustained 
viral response (SVR), which is equivalent to cure. Presently, 
the most effective treatment for chronic HCV infection is the 
combination of pegylated interferon (PEG-IFN) and ribavirin 
(RBV). This combination antiviral therapy provides a SVR in 
approximately 50% of patients,3 preventing HCV infection 
complications.4,5 Although ribavirin’s mechanism of action 
has not been fully elucidated, this nucleoside analogue has 
been shown to increase the antiviral effect of interferon (IFN) 
in HCV treatment in a dose-dependent manner.6 Therefore, 
improving tolerability and adherence to the optimal dose of 
RBV in HCV infected patients is crucial to ensure high SVR 
rates. In addition, RBV pre-treatment has been tested in cases 
of chronic hepatitis C and shown to increase the efficacy of 
IFN.7 Compliance during treatment and the dose of RBV are 
important factors for achieving SVR. Particularly, maintaining 
RBV dose is critical in patients with chronic hepatitis C who are 
treatment naive or who did not respond to a previous course 
of antiviral therapy.8-10 Several data indicate that the dose of 
RBV is very important in preventing relapse.8 A recent study 
demonstrated that patients treated with a weight-based RBV 
had a lower relapse rate than patients receiving fixed doses, 
especially in patients with high body weight.11
Despite this fundamental role of RBV, many aspects of the 
mechanism of action and of the optimal dose and duration of 
therapy remain to be defined. Some potential off-label use of this 
drug in more difficult-to-treat subjects has been proposed.12 A 
case of induction with RBV for six weeks before retreatment of 
a HCV infected relapsing patient is described below.
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A B S T R A C T
In this case, a new possible strategy for treatment of hepatitis C virus (HCV) relapsing 
patients is described. The target of anti-HCV therapy is sustained viral response, but 
strategies for improving sustained viral response in relapsing patients would be useful, 
and ribavirin is crucial for obtaining viral response. Six weeks of induction therapy with 
ribavirin were used to improve efficacy of standard combined antiviral therapy in a patient 
relapsing to standard therapy. In the present case, the patient had undergone a retreatment 
with the same regimen with the exception of the six-week induction period with ribavirin. 
Use of induction therapy with ribavirin in this case has allowed for a sustained viral 
response without prolonging the interferon exposure time in retreatment.
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Case presentation
A 61 year-old white female was casually detected with 
HCV infection in 2006 by physician screening. The patient 
showed aspartate aminotransferases (AST) and alanine 
aminotransferases (ALT) serum levels within the normal 
range or slightly raised in the previous 12 months (< 2 
normal range), WBC 6,700 cell/mmc and normal leukocyte 
formula,  Hb 14.1 g/dL,  PLT 218,000 cell/mmc, and 
HCV-RNA > 500,000 UI/mL, genotype 2a. She had hypertension 
under treatment with good control of blood pressure, body 
mass index (BMI) 34.2 kg/m2, total cholesterol 224 mg/dL, 
HDL 65 mg/dL, triglycerides 163 mg/dL, AST 31 U/L, and ALT 
32 U/L. It was decided to start treatment of HCV infection 
with PEG-IFNα2A 180 μg weekly plus RBV 1,200 mg/day 
(13.3 mg/kg/day) for 24 weeks. After one month of therapy, 
a rapid virological response was observed: transaminases 
were AST 30 U/L, ALT 36 U/L, and Hb dropped to 10.6 g/dL. 
Therapy was continued without changes and at the end 
of the treatment she presented a negative HCV-RNA, AST 
and ALT in normal ranges, and Hb 10.2 g/dL. Patient did not 
report missing any dose of RBV during control visits and the 
pill count confirmed this report.
However, one month after the end of antiviral therapy, 
she presented with HCV-RNA positive, AST 45 U/L, ALT 
53 U/L, and Hb 12.2 g/dL. At the three months follow-up, the 
patient showed HCV-RNA > 500,000 UI/mL and Hb 14 g/dL.
Because the patient was strongly motivated to undergo 
a new treatment, retreatment with off-label use of RBV was 
chosen. A clinical control after six months showed HCV-RNA 
> 500,000 UI/ml, AST 41 U/L, ALT 53 U/L, Hb 13.7 g/dL, and 
BMI 34 kg/m2. Therapy started with 13.3 mg/Kg/day of RBV 
alone for six weeks, followed by PEG-IFNα2A 180 μg weekly 
plus RBV 13.3 mg/Kg/day for 24 weeks. After six weeks of RBV 
alone, before starting combined therapy with PEG-IFN plus 
RBV, the patient had HCV-RNA 125,000 UI/mL, ALT 36 U/L, 
AST 38 U/L, Hb 10.7 g/dL, total cholesterol 211 mg/dL, HDL 
83 mg/dL, triglycerides 91 mg/dL. After one month of combined 
antiviral therapy, negative HCV-RNA, transaminases in the 
normal range, and Hb 10.4 mg/dL were observed. At the end 
of treatment, HCV-RNA was negative, Hb 9.5 g/dL, and AST 
and ALT were in normal range. Epoietin was neither used in 
the first nor in the second treatment course.
Six months after the end of anti-HCV therapy, the patient 
had normal aminotransferases serum levels and a sustained 
viral response.
Discussion
In this case a new possible strategy for treating relapsing 
patients is described. Six-week induction therapy with RBV 
was used to improve efficacy of the standard combined 
antiviral therapy. RBV is a direct antiviral agent but has 
also been shown to modulate immune response. RBV 
inhibits inosine 5’ monophospate dehydrogenase, which is 
responsible for the intracellular synthesis of guanine, and 
consequentially reduces RNA viral replication.13 Furthermore, 
a recent study suggests that RBV potentiates the anti-HCV 
effect of IFN, augmenting the induction of interferon-
stimulated genes in patients treated for HCV infection.14 
Merli et al. indicate that RBV pre-treatment increased the 
tolerability of the antiviral therapy, and improved its efficacy 
in liver transplant patients.15
In this patient, the six-week induction therapy with RBV 
produced a slight decline of HCV-RNA plasma level, and it may 
be hypothesized that this strategy enhanced viral clearance 
during combination therapy. Use of induction therapy with 
RBV in this case seemed to assure a good adherence to 
combination treatment, probably because it makes the side-
effects of the two drugs asynchronous, which might improve 
patient’s compliance. on the basis of RBV pharmacokinetics, 
a six-week RBV pre-treatment could optimize the preparation 
of the hepatic cell machinery to IFN activity. In this patient 
RBV monotherapy was capable of significantly reducing 
HCV-RNA levels, in accordance with the literature.16,17
A particularity in the present case is that the patient had 
undergone retreatment with the same regimen, with the 
exception of induction for six weeks with RBV. Currently, 
relapsing patients are treated for a longer period with 
combination therapy to improve the success rate, because 
it is known that patients retreated with the same regimen, 
even if the type of interferon is changed, have a very low 
response rate.18
RBV pre-treatment improved efficacy in this HCV relapsing 
patient. Moreover, HCV-RNA decline during pre-treatment with 
RBV allows one to make an useful prediction about treatment 
results. In the present case the patient had undergone a 
re-treatment with the same regimen with the exception of 
induction with six weeks of RBV. In conclusion, if further 
studies should confirm this observation, there would be a 
reduction of the combination therapy time, of these patients’ 
management costs, and of drug-induced adverse events. 
Randomized trials are needed to confirm the effectiveness 
of this RBV induction therapy strategy, which may be an 
important new method to achieve SVR in HCV-infected 
relapsing patients. 
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